Clinical Trial Search

Primary: Proportion of Women Who Benefited of Performing Upfront Sentinel Lymph Node (SLN) Biopsy Ductal Carcinoma in Situ — 51 Participants

Primary: Patients With Reduction in Incidental Radiation — 46 Participants

Primary: Percentages of Participants by EORTC Breast Cosmetic Rating Score at 24 Months Post-radiation Therapy — 17; 26; 24; 11 Participants

Primary: Success Rate in Removing Sentinel Lymph Nodes by Thoracoscopy — 31 participants

Primary: Local Inbreast Breast Tumor Recurrence (IBTR) Rate — 4.3 Percentage of participants with IBTR

Primary: Number of Participants With Breast Cancer Recurrence, Including Recurrent DCIS and New Contralateral Tumours — 103; 120 Participants — p=0.33

Primary: Quality of Life as Measured by the Breast Q — 61.9; 57.6; 74.2; 64.2 score on a scale

Primary: Percentage of Patients Who Are Free of Serious Treatment Related Toxicity — 50; 49 Participants

Primary: 5-year Disease-Free Survival — 84.4; 87.8 percentage of participants — p=0.004

Primary: Collect Data to Refine and Verify the Tumor Detection Algorithm. — 11.3 Percentage

Primary: Change in Baseline of Cancer Cell Protein Levels of Human Epidermal Growth Factor Receptor (HER) Family Members (HER1-4) Following Neoadjuvant Endocrine Therapy. — 1…

Primary: Ipsilateral Recurrence Rate — 0 participants

Primary: Percent Change in Time of Circulating Estradiol SPE in Each Arm — -89; -85; -60 percent change

Primary: Number of Participants Who Are Adherent to the Diet Restriction — 28 participants

Primary: Feasibility of PBI Directed External Radiotherapy as Measured by Percentage of Participants Achieving a Dosimetrically Satisfactory Treatment Plan — 100; 100 percentage…

Primary: Number of Participants Experiencing Acute, Late Skin, and Subcutaneous Toxicity — 0 Participants

Primary: Feasibility and Local Control of Early Breast Cancer Treated by Partial Breast Irradiation Using Different Radiation Doses Determined by Completion. — 98; 101; 124…

Primary: Median Change in 6-month Tumor Volume Compared to Baseline Using Mammography — -5.0 change in tumor volume (mm) — p=0.07

Primary: Early and Intermediate Toxicity — 40; 28 participants

Primary: Complete Response Rate — 2; 8 Participants

Primary: Mean Total MRI Functional Tumor Volume (FTV) Change From Baseline to Month 3 (V3) — -1.93 cubic centimeters — p=<0.001

Primary: Number of Participants With a Pathological Complete Response — 21; 24; 99; 89 participants

Primary: 18F-FES Uptake in DCIS — 1.43 SUV

Primary: False Negative Rate (FNR) for Sentinel Lymph Node (SLN) Surgery After Chemotherapy When at Least 2 SLNs Were Excised in Women Initially Presenting With Biopsy-proven cN1…

Primary: (Phase A Only) Selection of Dose of LUM015 to be Used in Future Breast Trials — 2.1; 4.7; 4.2 Ratio

Primary: The Mean Distance Between the Image-defined and Palpation-defined Edges of the Tumor. — 7.2 mm

Primary: Pathological Response for Basal Group 2 — 16; 14; 5; 11 Participants

Primary: The Residual Cancer Burden Grade III (RCB-III). — 23; 37; 14; 6 Participants

Primary: Number of Patients With Local Recurrence — 10 participants

Primary: Patients With All Positive Margins Correctly Identified With the Device — 5 Patients w/ all positives identified